Advertisement


Rami Manochakian, MD, on NSCLC: Clinical Implications of Findings on Nivolumab Plus Chemotherapy

2022 ASCO Annual Meeting

Advertisement

Rami Manochakian, MD, of Mayo Clinic Florida, discusses the phase II findings of the NADIM II trial, which confirmed that, in terms of pathologic complete response as well as the feasibility of surgery, combining nivolumab and chemotherapy was superior to chemotherapy alone as a neoadjuvant treatment for locally advanced, resectable stage IIIA non–small cell lung cancer (Abstract 8501).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The NADIM II Trial is a randomized open label Phase II trial of Neoadjuvant Nivolumab with a regimen, chemotherapy regimen, of carboplatin paclitaxel versus chemotherapy alone, given in three cycles for patients with Stage 3A non-small cell lung cancer. After the three cycle of the neoadjuvant therapy, patient proceeded with surgery, and following surgery, patient received six months of Adjuvant Nivolumab. This study was done by the Spanish Lung Cancer Group Trial. The study primary endpoint was the pathological complete response rate, and secondary endpoint, there was the major pathological response rate, as well as response rate and also adverse events. This study is important, since it's really looking in particular at the Stage 3A patients with non-small cell lung cancer. This is a challenging population. There is an evolving research and trials testing in particularly this population. We have recently reported CheckMate 816, that led to the approval of Neoadjuvant Nivolumab and chemotherapy in patients from Stage 1B to Stage 3. We have the Adjuvant therapy also approved in a patient with Stage 3. We have the patient who don't undergo resection, and they receive concurrent chemoradiation. So, what this trial is come as a validation to the CheckMate 816, looking in particularly to this patient of a Stage 3A. The result of the studies were positive. The primary endpoint, which was the pathological complete response rate, was about 36% versus 7% in the patients who did not get the immunotherapy and received the chemotherapy alone. The secondary endpoint, the major pathological response rate, which means the 10% or less of viable tumor in the resected specimen and lymph node, was 52% versus 13%. The overall response rate was 74% versus 48%. And the adverse event, there was some modest increase in the adverse event, in particularly the Grade 3, 4. It was about 24% versus 20%. This study is, again, comes as a validation for the role of Neoadjuvant chemotherapy and immunotherapy in patient with Stage 3A. This is something that has continued to evolve, as I mentioned earlier, and it's definitely set a standard of care option as one of the option for patients who potentially have resectable Stage 3 non-small cell lung cancer to receive chemotherapy and immunotherapy, followed by surgery and followed by Adjuvant immunotherapy.

Related Videos

Gynecologic Cancers
Immunotherapy

Ursula A. Matulonis, MD, and Ignace Vergote, MD, PhD, on Cervical Cancer: Interim Results on Tisotumab Vedotin-tftv Plus Pembrolizumab

Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, and Ignace Vergote, MD, PhD, of Belgium’s University Hospitals Leuven, discuss interim safety and efficacy results from a third dose-expansion cohort evaluating first-line tisotumab vedotin-tftv plus pembrolizumab in patients with recurrent or metastatic cervical cancer. Data on the combination showed durable antitumor activity with a manageable safety profile (Abstract 5507).

Michael J. Overman, MD, and Takayuki Yoshino, PhD, MD, on Colorectal Cancer: Phase III Data on Panitumumab or Bevacizumab Plus mFOLFOX6

Michael J. Overman, MD, of The University of Texas MD Anderson Cancer Center, and Takayuki Yoshino, PhD, MD, of the National Cancer Center Hospital East, Japan, discuss results from the PARADIGM trial, the first prospective study to test the superiority of panitumumab vs bevacizumab in combination with standard doublet first-line chemotherapy for patients with RAS wild-type and left-sided metastatic colorectal cancer. The study showed that panitumumab improved overall survival in combination with mFOLFOX6, which may establish a standard first-line combination regimen for this population (Abstract LBA1).

Prostate Cancer

Alicia K. Morgans, MD, MPH, and Michael S. Hofman, MBBS, on Prostate Cancer: New Data on Lutetium-177–PSMA-617 (LuPSMA) vs Cabazitaxel

Alicia K. Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Michael S. Hofman, MBBS, of Peter MacCallum Cancer Centre, University of Melbourne, discuss follow-up results on LuPSMA vs cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel treatment. The findings suggest that LuPSMA is a suitable option for this population, with fewer adverse events, higher response rates, improved patient-reported outcomes, and similar overall survival compared with cabazitaxel (Abstract 5000).

Breast Cancer

Stephanie Walker on Increasing the Participation of Black Women With Metastatic Breast Cancer in Clinical Trials

Stephanie Walker, a former nurse and current activist with the Metastatic Breast Cancer Alliance, discusses findings from the BECOME project (Black Experience of Clinical Trials and Opportunities for Meaningful Engagement). They show that, even though Black patients comprise between 4% and 6% of all clinical trial participants, Black women with metastatic breast cancer are willing to consider taking part if steps were taken to increase their awareness, build trust through clear communication with health-care providers, involve people of shared racial/ethnic identity and health experience, and help patients find and access trials (Abstract 1014).

Bladder Cancer

Sumanta K. Pal, MD, on Urothelial Carcinoma: New Results on Cabozantinib Plus Atezolizumab

Sumanta K. Pal, MD, of City of Hope National Medical Center, discusses findings from the COSMIC-021 study, which showed that cabozantinib plus atezolizumab demonstrated encouraging clinical activity with manageable toxicity in patients with inoperable locally advanced or metastatic urothelial carcinoma. The combination was administered as first-line therapy in cisplatin-based chemotherapy–eligible and –ineligible patients and as second- or later-line treatment in those who received prior immune checkpoint inhibitors (Abstract 4504).

Advertisement

Advertisement




Advertisement